Mundipharma bags rights to sell Janssen’s Invokana, Vokanamet
Janssen Pharmaceutica | September 06, 2017
Janssen Pharmaceutica has entered into an exclusive agreement with Mundipharma under which the latter will distribute its diabetes drugs Invokana and Vokanamet in countries in the European Economic Area (EEA) and Switzerland. Currently the deal relates to territories where the products have obtained pricing and reimbursement approvals, but additional EEA countries may be added after further agreements are in place.